-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of neoadjuvant therapy, the efficacy of PD-1-targeted checkpoint inhibitors in the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) has been verified, but the response rate is still unsatisfactory.
Leidner et al.
Before confirming surgical resection, it is safe to add stereotactic radiotherapy (SBRT) to the anti-PD-1 treatment, or it can improve the pathological remission rate compared with single use of checkpoint inhibitors
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinomaThis is a single-center phase Ib clinical trial that recruits HNSCC patients with locally advanced HPV positive (+) or negative (-) who have not been treated before.
A: Neoadjuvant treatment before surgical resection; B: RECIST response during surgery
A: Neoadjuvant treatment before surgical resection; B: RECIST response during surgeryFrom 2018 to 2019, a total of 21 patients were recruited to receive neoadjuvant therapy.
A total of 21 patients were recruited to receive neoadjuvant therapy, and all patients were well tolerated.
In patients with head and neck cancer, radiotherapy combined with immunotherapy at the tumor site before surgery is safe and can enable patients to obtain a higher mPR rate of immunity
Original source:
Original source:Leidner Rom, Crittenden Marka, Young Kristina et al.
org/10.
1136/jitc-2021-002485">Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
in this message
